bullish
Best Idea of 2025: Medexus Pharmaceuticals
190 Views03 Mar 2025 09:26
Medexus (MDP.TO / MEDXF) is my best idea for 2025. The stock trades at a distressed valuation despite the current launch of a new drug that could double revenue and triple EBITDA within 3 years.
What is covered in the Full Insight:
- Introduction to Medexus Pharmaceuticals
- Company Overview
- GRAFAPEX Drug Launch and Market Potential
- Financial Projections and Valuation
- Risks and Investor Concerns
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
x